ACE and COVID-19: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers which are commonly prescribed in hypertensive and diabetic patients [38] were accused in some reports of having a drastic effect on COVID-19 victims [39, 40] as by inhibiting the action of ACE an upregulation in ACE 2 occurs which facilitate more SARS-CoV-2 entrance to cells with further replication and intensified symptoms yet this claim was countered by other reports on some animal models [41].